Andrei Barasch1,2, Judith Raber-Durlacher3, Joel B Epstein4,5, James Carroll6. 1. Department of Medicine, Weill Cornell Medical College, 528 E 68th Street, New York, NY, 10065, USA. barasaff@cs.com. 2. Department of Periodontology, ACTA University of Amsterdam, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands. barasaff@cs.com. 3. Department of Periodontology, ACTA University of Amsterdam, Gustav Mahlerlaan 3004, 1081 LA, Amsterdam, The Netherlands. 4. Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 5. Division of Otolaryngology and Head and Neck Surgery, City of Hope, Duarte, CA, USA. 6. THOR Photomedicine Ltd, Chesham, UK.
Abstract
PURPOSE: Low-level laser therapy (LLLT) efficacy for the prevention of cancer treatment-induced oral mucositis (OM) has been amply described. However, potential protection of malignant cells remains a legitimate concern for clinicians. We tested LLLT-induced protection from ionizing radiation killing in both malignant and normal cells. METHODS: We treated six groups each of normal human lymphoblasts (TK6) and human leukemia cells (HL60) with He-Ne LLLT (632.8 nm, 35 mW, CW, 1 cm(2), 35 mW/cm(2) for 3-343 s, 0.1-12 J/cm(2)) prior to exposure to ionizing radiation (IR). Cells were then incubated and counted daily to determine their survival. Optimization of IR dose and incubation time was established prior to testing the effect of LLLT. RESULTS: Growth curves for both cell lines showed significant declines after exposure to 50-200 cGy IR when compared to controls. Pre-radiation exposure to LLLT (4.0 J/cm(2)) followed by 1-h incubation blocked this decline in TK6 but not in HL60 cells. The latter cells were sensitized to the killing effects of IR in a dose-dependent manner. CONCLUSION: This study shows that pre-IR LLLT treatment results in a differential response of normal vs. malignant cells, suggesting that LLLT does not confer protection and may even sensitize cancer cells to IR killing.
PURPOSE: Low-level laser therapy (LLLT) efficacy for the prevention of cancer treatment-induced oral mucositis (OM) has been amply described. However, potential protection of malignant cells remains a legitimate concern for clinicians. We tested LLLT-induced protection from ionizing radiation killing in both malignant and normal cells. METHODS: We treated six groups each of normal human lymphoblasts (TK6) and humanleukemia cells (HL60) with He-Ne LLLT (632.8 nm, 35 mW, CW, 1 cm(2), 35 mW/cm(2) for 3-343 s, 0.1-12 J/cm(2)) prior to exposure to ionizing radiation (IR). Cells were then incubated and counted daily to determine their survival. Optimization of IR dose and incubation time was established prior to testing the effect of LLLT. RESULTS: Growth curves for both cell lines showed significant declines after exposure to 50-200 cGy IR when compared to controls. Pre-radiation exposure to LLLT (4.0 J/cm(2)) followed by 1-h incubation blocked this decline in TK6 but not in HL60 cells. The latter cells were sensitized to the killing effects of IR in a dose-dependent manner. CONCLUSION: This study shows that pre-IR LLLT treatment results in a differential response of normal vs. malignant cells, suggesting that LLLT does not confer protection and may even sensitize cancer cells to IR killing.
Authors: Jan E Clarkson; Helen V Worthington; Susan Furness; Martin McCabe; Tasneem Khalid; Stefan Meyer Journal: Cochrane Database Syst Rev Date: 2010-08-04
Authors: A Barasch; D E Peterson; J M Tanzer; J A D'Ambrosio; K Nuki; M M Schubert; J C Franquin; J Clive; P Tutschka Journal: Cancer Date: 1995-12-15 Impact factor: 6.860
Authors: Jan Magnus Bjordal; Rene-Jean Bensadoun; Jan Tunèr; Lucio Frigo; Kjersti Gjerde; Rodrigo Ab Lopes-Martins Journal: Support Care Cancer Date: 2011-06-10 Impact factor: 3.603
Authors: Heliton S Antunes; Daniel Herchenhorn; Isabele A Small; Carlos M M Araújo; Celia Maria Pais Viégas; Elida Cabral; Mariana P Rampini; Pedro C Rodrigues; Tereza G P Silva; Elza M S Ferreira; Fernando L Dias; Carlos G Ferreira Journal: Radiother Oncol Date: 2013-09-14 Impact factor: 6.280
Authors: Linda S Elting; Dorothy M Keefe; Stephen T Sonis; Adam S Garden; F K L Spijkervet; Andrei Barasch; Roy B Tishler; Thomas P Canty; Mahesh K Kudrimoti; Montserrat Vera-Llonch Journal: Cancer Date: 2008-11-15 Impact factor: 6.860
Authors: Rajesh V Lalla; Joanne Bowen; Andrei Barasch; Linda Elting; Joel Epstein; Dorothy M Keefe; Deborah B McGuire; Cesar Migliorati; Ourania Nicolatou-Galitis; Douglas E Peterson; Judith E Raber-Durlacher; Stephen T Sonis; Sharon Elad Journal: Cancer Date: 2014-02-25 Impact factor: 6.860
Authors: Thaís Bianca Brandão; Karina Morais-Faria; Ana Carolina Prado Ribeiro; César Rivera; João Victor Salvajoli; Marcio Ajudarte Lopes; Joel B Epstein; Praveen R Arany; Gilberto de Castro; Cesar Augusto Migliorati; Alan Roger Santos-Silva Journal: Support Care Cancer Date: 2018-02-08 Impact factor: 3.603
Authors: Judith A E M Zecha; Judith E Raber-Durlacher; Raj G Nair; Joel B Epstein; Stephen T Sonis; Sharon Elad; Michael R Hamblin; Andrei Barasch; Cesar A Migliorati; Dan M J Milstein; Marie-Thérèse Genot; Liset Lansaat; Ron van der Brink; Josep Arnabat-Dominguez; Lisette van der Molen; Irene Jacobi; Judi van Diessen; Jan de Lange; Ludi E Smeele; Mark M Schubert; René-Jean Bensadoun Journal: Support Care Cancer Date: 2016-03-16 Impact factor: 3.603
Authors: Natalia V Kalmykova; Anna V Shcherbanyuk; Sergei I Moiseev; Natalia V Bichkova; Natalia I Davidova; Kira A Samoilova Journal: Laser Ther Date: 2019-09-30
Authors: René-Jean Bensadoun; Joel B Epstein; Raj G Nair; Andrei Barasch; Judith E Raber-Durlacher; Cesar Migliorati; Marie-Thérèse Genot-Klastersky; Nathaniel Treister; Praveen Arany; Joy Lodewijckx; Jolien Robijns Journal: Cancer Med Date: 2020-10-26 Impact factor: 4.452